 |
|
|
| |
Ritonavir boosting of the HCV protease inhibitor danoprevir (DNVr) significantly reduces reactive metabolite formation in vitro and in vivo
|
| |
| |
Reported by Jules Levin
APASL Liver Week 2013; 6-10 June, Singapore
P. Goelzer,1 P.N. Morcos,1 J.Q. Tran,2* B. Wen,1 N.S. Shulman,3 B.J. Brennan,1 J. Hammond,1 T. Singer,4 P. Smith1
1Hoffmann-La Roche Inc, Nutley, NJ, USA; 2Hoffmann-La Roche Inc, Palo Alto, CA, USA; 3Genentech, South San Francisco, CA, USA; 4F. Hoffmann-La Roche Ltd, Basel, Switzerland
Current affiliations: * Biogen Idec, Cambridge, MA, USA; GlaxoSmithKline, King of Prussia, PA, USA; d3 Medicine, Montville, NJ, USA
RITONAVIR SUBSTANTIALLY REDUCES REACTIVE METABOLITE FORMATION OF THE HCV PROTEASE INHIBITOR DANOPREVIR BOTH IN VITRO AND IN VIVO, EASL 2012 Barcelona Spain Apr 18-22.......http://www.natap.org/2012/EASL/EASL_34.htm
|
| |
|
|
|
|
|
